Lantheus Holdings Inc. (LNTH) exhibits 61.1% gross margins and 20.3% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 18.0x enterprise multiple and 6.5% implied options volatility.
Sustained 61.1% gross profitability converts into 20.2% operating margin and 20.3% ROIC, outpacing sector cost of capital.
ROIC: 20.3% // GM: 61.1%YoY revenue trajectory of +0.5% paired with 4.90% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +0.5% // FCF YLD: 4.90%Altman Z-Score of 5.34 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.34 // F-SCORE: 7/9Trading at 28.0x trailing P/E (26.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 28.0x // EV/EBITDA: 18.0xOptions market prices a ±6.5% implied move with a 0.82 put/call ratio around $98.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.82Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend 15.2% net margins.
NET MARGIN: 15.2% // D/E: 0.44x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for LNTH & activate live FRED threshold breach alerts.